Friday, 23 November 2018

A Thanksgiving Message from BioLargo and an Important Press Release on Micropollutant Treatment by the AOS


Dear Stockholder,

First, let me wish you all a Happy Thanksgiving and say THANK YOU! 













We have so much to be thankful for, and a few highlights deserve a mention in light of this special holiday:
  • The BioLargo Technology. When we first met Ken Code over a decade ago, he shared the gift of his scientific discoveries and the enormous and important duty that comes with unique and innovative technologies like ours designed to make the world a better place. 
  • You, and each of our investors. Without our investors’ continued support, our journey and our technologies would be impossible. Our journey – from idea to fully developed and finished products, and all the barriers that come with it, is most certainly not for the faint of heart. We have had to fight for every inch and the journey has most certainly tested our resolve and patience. Rest assured, we are not deterred, and because of our continual progress, we are more excited than ever before. And we thank you for your support on this journey.
  • Team members. We have assembled a diverse team of highly qualified innovators, engineers, scientists, and operators that are fearless and driven by our mission. They are special and critical to our ongoing success.
  • Grant Supporters. We have now received more than 60 grants from a host of Canadian federal and provincial agencies as well as industry members in support of our clean water technology. The pursuit of such an ambitious vision like ours that can impact the world for good would never be possible without support like this.  It is and will continue to be critical to our ongoing success.
  • Critics. Yes, we are grateful for the insights of our critics. “Iron sharpens iron” – and our tools have been finely honed to razor sharpness. Remember, in each of our pursuits – clean air, clean water and advanced wound care – we are an innovator presenting novel scientific discoveries that have never been seen before in such meaningful pursuits. Because our technologies are novel and unprecedented, our challenge has been to prove, prove and prove again. 

As an example, we have just released a press release detailing a very important recent study where the AOS was shown, by an expert 3rd party research lab at the University of Alberta, to effectively eliminate specific micropollutant pharmaceuticals that are a major problem in municipal wastewater treatment. Because there is no economically feasible solution for these contaminants in municipal wastewater treatment, these results make the AOS a breakthrough in advanced municipal wastewater treatment. The press release is below.

Our continued success in science and now our growing commercial success reminds us to be THANKFUL and excited for 2019.

Happy Thanksgiving,

Dennis Calvert
President and CEO
BioLargo, Inc.


Press Release below



BioLargo's Advanced Oxidation System (AOS) Test Data Show Breakthrough to Treat and Reduce the Toxicity of Micropollutants Associated with Municipal Wastewater

Westminster, CA - November 20, 2018 - BioLargo, Inc. (OTCQB:BLGO), developer of sustainable science and technologies and a full-service environmental engineering company, today announced the completion of a third-party study indicating the company's Advanced Oxidation System (AOS) water treatment technology can eliminate certain toxic micropollutant contaminants associated with municipal wastewater. Micropollutants are widespread and persistent contaminants of significant concern to regulators due to environmental and human health concerns, and are difficult to treat using conventional wastewater treatment technologies (such as UV and biological treatment). Consequently, discharge of micropollutants in municipal wastewater effluents is currently a high priority issue for regulators and municipalities. Due to the lack of existing economically viable solutions for the elimination of micropollutants from municipal wastewater, these findings make the AOS a breakthrough in advanced municipal wastewater treatment.

BioLargo had previously reported on a third-party study conducted in collaboration with researchers at the Centre Des Technologies de L'Eau suggesting its AOS technology effectively removes certain pharmaceutical by-products (i.e., micropollutants) from water (Link here).
In this follow-up study conducted by Dr. Greg Goss, an expert in aquatic toxicology at the University of Alberta, in collaboration with BioLargo's Canadian subsidiary BioLargo Water, Inc., Dr. Goss examined the environmental safety of AOS-treated municipal wastewater to demonstrate it did not produce toxic by-products, and whether the AOS' ability to eliminate pharmaceuticals from water would improve the environmental safety and water quality of municipal wastewater "spiked" with high concentrations of micropollutant contaminants of particular concern to regulators.

This study succeeded on both fronts, demonstrating that water treated by the AOS technology was non-toxic to certain aquatic organisms typically used for testing whole effluent toxicity for the EPA's National Pollutant Discharge Elimination System (NPDES) Permits Program, such as
Daphnia and rainbow trout, as well as zebrafish embryos. Additionally, the AOS eliminated biomarker responses of municipal wastewater that has been experimentally contaminated (spiked) with compounds (benzo[a]pyrene and 17β-estradiol) known to negatively affect those organisms.

Further, the study showed that the AOS reduces the well-documented aberrant endocrine disrupting chemical (EDC) effects of 17β-estradiol (an estrogen derivative) on rainbow trout. AOS was able to reduce both the normal EDC effects of municipal wastewater on rainbow trout and was also successful in removing 17β-estradiol from municipal wastewater spiked with much higher levels of the hormone.

These results represent promising evidence that the AOS can remove micropollutants that are an emerging concern to the water treatment industry. Given that micropollutants are bioactive and persistent contaminants that are not removed by traditional wastewater treatment methods, AOS has the potential to fill an important niche treatment gap with growing demand: effective and cost-efficient removal of micropollutants in wastewater treatment.

Dr. Greg Goss commented on the results, "More work is needed, but it appears that the AOS treatment is a major technical breakthrough for the removal of micropollutants from wastewater."

This work was funded in part by the Canadian Natural Science and Engineering Research Council (NSERC) and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

No comments:

Post a comment